166 related articles for article (PubMed ID: 28776371)
1. Asymmetric Formal Synthesis of the Long-Acting DPP-4 Inhibitor Omarigliptin.
Peng F; Chen Y; Chen CY; Dormer PG; Kassim A; McLaughlin M; Reamer RA; Sherer EC; Song ZJ; Tan L; Tudge MT; Wan B; Chung JYL
J Org Chem; 2017 Sep; 82(17):9023-9029. PubMed ID: 28776371
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity-relationship of amide and sulfonamide analogs of omarigliptin.
Chen P; Feng D; Qian X; Apgar J; Wilkening R; Kuethe JT; Gao YD; Scapin G; Cox J; Doss G; Eiermann G; He H; Li X; Lyons KA; Metzger J; Petrov A; Wu JK; Xu S; Weber AE; Yan Y; Roy RS; Biftu T
Bioorg Med Chem Lett; 2015 Dec; 25(24):5767-71. PubMed ID: 26546218
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, and Evaluation of a Series of Novel Super Long-Acting DPP-4 Inhibitors for the Treatment of Type 2 Diabetes.
Zhang C; Ye F; Wang J; He P; Lei M; Huang L; Huang A; Tang P; Lin H; Liao Y; Liang Y; Ni J; Yan P
J Med Chem; 2020 Jul; 63(13):7108-7126. PubMed ID: 32452679
[TBL] [Abstract][Full Text] [Related]
4. Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes.
Biftu T; Sinha-Roy R; Chen P; Qian X; Feng D; Kuethe JT; Scapin G; Gao YD; Yan Y; Krueger D; Bak A; Eiermann G; He J; Cox J; Hicks J; Lyons K; He H; Salituro G; Tong S; Patel S; Doss G; Petrov A; Wu J; Xu SS; Sewall C; Zhang X; Zhang B; Thornberry NA; Weber AE
J Med Chem; 2014 Apr; 57(8):3205-12. PubMed ID: 24660890
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of [(14) C]omarigliptin.
Ren S; Gauthier D; Marques R; Helmy R; Hesk D
J Labelled Comp Radiopharm; 2016 Aug; 59(10):386-90. PubMed ID: 27334864
[TBL] [Abstract][Full Text] [Related]
6. Novel tetrahydropyran analogs as dipeptidyl peptidase IV inhibitors: Profile of clinical candidate (2R,3S,5R)-2- (2,5-difluorophenyl)-5-(4,6-dihydropyrrolo [3,4-c]pyrazol-5-(1H)-yl)tetrahydro-2H-pyran-3-amine (23) [corrected].
Biftu T; Qian X; Chen P; Feng D; Scapin G; Gao YD; Cox J; Roy RS; Eiermann G; He H; Lyons K; Salituro G; Patel S; Petrov A; Xu F; Xu SS; Zhang B; Caldwell C; Wu JK; Lyons K; Weber AE
Bioorg Med Chem Lett; 2013 Oct; 23(19):5361-6. PubMed ID: 23972441
[TBL] [Abstract][Full Text] [Related]
7. Organocatalytic one-pot asymmetric synthesis of 4H,5H-pyrano[2,3-c]pyrazoles.
Enders D; Grossmann A; Gieraths B; Düzdemir M; Merkens C
Org Lett; 2012 Aug; 14(16):4254-7. PubMed ID: 22852800
[TBL] [Abstract][Full Text] [Related]
8. Asymmetric synthesis of a potent, aminopiperidine-fused imidazopyridine dipeptidyl peptidase IV inhibitor.
Xu F; Corley E; Zacuto M; Conlon DA; Pipik B; Humphrey G; Murry J; Tschaen D
J Org Chem; 2010 Mar; 75(5):1343-53. PubMed ID: 20128619
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic-pharmacodynamic (dipeptidyl peptidase-4 inhibition) model to support dose rationale in diabetes patients, including those with renal impairment, for once-weekly administered omarigliptin.
Jain L; Chain ASY; Tatosian DA; Hing J; Passarell JA; Kauh EA; Lai E
Br J Clin Pharmacol; 2019 Dec; 85(12):2759-2771. PubMed ID: 31454094
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus.
Addy C; Tatosian D; Glasgow XS; Gendrano IN; Kauh E; Martucci A; Johnson-Levonas AO; Selverian D; Matthews CZ; Gutierrez M; Wagner JA; Aubrey Stoch S
Clin Ther; 2016 Mar; 38(3):516-30. PubMed ID: 26869191
[TBL] [Abstract][Full Text] [Related]
11. Omarigliptin for the treatment of type 2 diabetes.
Tan X
Endocrine; 2016 Oct; 54(1):24-31. PubMed ID: 27372109
[TBL] [Abstract][Full Text] [Related]
12. Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once-weekly dipeptidyl peptidase-4 inhibitor, in healthy Japanese men.
Tsuchiya S; Friedman E; Addy C; Wakana A; Tatosian D; Matsumoto Y; Suzuki H; Kauh E
J Diabetes Investig; 2017 Jan; 8(1):84-92. PubMed ID: 27182005
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once-Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, After Single and Multiple Doses in Healthy Subjects.
Krishna R; Addy C; Tatosian D; Glasgow XS; Gendrano Iii IN; Robberechts M; Haazen W; de Hoon JN; Depré M; Martucci A; Peng JZ; Johnson-Levonas AO; Wagner JA; Stoch SA
J Clin Pharmacol; 2016 Dec; 56(12):1528-1537. PubMed ID: 27225334
[TBL] [Abstract][Full Text] [Related]
14. Omarigliptin for the treatment of type 2 diabetes mellitus.
Evans PM; Bain SC
Expert Opin Pharmacother; 2016 Oct; 17(14):1947-52. PubMed ID: 27466703
[TBL] [Abstract][Full Text] [Related]
15. Omarigliptin: first global approval.
Burness CB
Drugs; 2015 Nov; 75(16):1947-52. PubMed ID: 26507988
[TBL] [Abstract][Full Text] [Related]
16. Effects of omarigliptin on glucose variability and oxidative stress in type 2 diabetes patients: A prospective study.
Ohara M; Nagaike H; Fujikawa T; Kohata Y; Ogawa M; Omachi T; Sasajima R; Chiba H; Ara T; Sugawara A; Hiromura M; Terasaki M; Mori Y; Fukui T; Hirano T; Yokoyama H; Yamagishi SI
Diabetes Res Clin Pract; 2021 Sep; 179():108999. PubMed ID: 34390762
[TBL] [Abstract][Full Text] [Related]
17. Novel series of 3-amino-N-(4-aryl-1,1-dioxothian-4-yl)butanamides as potent and selective dipeptidyl peptidase IV inhibitors.
Nitta A; Fujii H; Sakami S; Satoh M; Nakaki J; Satoh S; Kumagai H; Kawai H
Bioorg Med Chem Lett; 2012 Dec; 22(23):7036-40. PubMed ID: 23072865
[TBL] [Abstract][Full Text] [Related]
18. Asymmetric synthesis of highly functionalized tetrahydropyran DPP-4 inhibitor.
Xu F; Zacuto MJ; Kohmura Y; Rosen J; Gibb A; Alam M; Scott J; Tschaen D
Org Lett; 2014 Oct; 16(20):5422-5. PubMed ID: 25269068
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus: A systemic review and meta-analysis.
Wang X; Li X; Qie S; Zheng Y; Liu Y; Liu G
Medicine (Baltimore); 2018 Aug; 97(34):e11946. PubMed ID: 30142816
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes.
Home P; Shankar RR; Gantz I; Iredale C; O'Neill EA; Jain L; Pong A; Suryawanshi S; Engel SS; Kaufman KD; Lai E
Diabetes Res Clin Pract; 2018 Apr; 138():253-261. PubMed ID: 29079379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
